BECTON DICKINSON INFUSION THERAPY UK
Get an alert when BECTON DICKINSON INFUSION THERAPY UK files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
—
Latest balance sheet
Net assets
£92m
+13.4% highest in 3 filed years
Employees
361
-2.7% lowest in 3 filed years
Profit before tax
£7.4m
+13.7% highest in 3 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
The company has net current assets of £75,000,000 (2024: £31,471,000) at the year end and is dependent on the ongoing financial support of its ultimate parent undertaking, Becton, Dickinson and Company, who has confirmed to the directors of the company that this support will continue until 30 June 2027, in order to enable the company to fulfil its financial commitments as and when liabilities fall due.
-
Going-concern uncertainty disclosed
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-09-30
| Metric | Trend | 2023-09-30 | 2024-09-30 | 2025-09-30 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £71,758,000 | £62,713,000 | £64,877,000 | +3.5% | |
| Operating profit | £7,236,000 | £5,596,000 | £5,681,000 | +1.5% | |
| Profit before tax | £7,271,000 | £6,532,000 | £7,428,000 | +13.7% | |
| Net profit | £6,209,000 | £6,545,000 | £10,926,000 | +66.9% | |
| Cash | — | — | — | — | |
| Total assets less current liabilities | £89,267,000 | £94,789,000 | £102,249,000 | +7.9% | |
| Net assets | £74,378,000 | £81,148,000 | £92,056,000 | +13.4% | |
| Equity | £74,378,000 | £81,148,000 | £92,056,000 | +13.4% | |
| Average employees | 463 | 371 | 361 | -2.7% | |
| Wages | £20,144,000 | £15,932,000 | £16,780,000 | +5.3% | |
| Directors' remuneration | — | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|---|
| Operating margin | 10.1% | 8.9% | 8.8% | |
| Net margin | 8.7% | 10.4% | 16.8% | |
| Return on capital employed | 8.1% | 5.9% | 5.6% | |
| Gearing (liabilities / total assets) | — | 21.9% | 21.9% | |
| Current ratio | — | 4.43x | 5.79x | |
| Interest cover | 26.51x | 53.30x | 62.43x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 3 times since incorporation
- BECTON DICKINSON INFUSION THERAPY UK 1999-03-16 → present
- OHMEDA 1993-07-01 → 1999-03-16
- BOC HEALTH CARE 1976-12-31 → 1993-07-01
- MEDISHIELD (HARLOW) LIMITED 1954-07-26 → 1976-12-31
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“The company has net current assets of £75,000,000 (2024: £31,471,000) at the year end and is dependent on the ongoing financial support of its ultimate parent undertaking, Becton, Dickinson and Company, who has confirmed to the directors of the company that this support will continue until 30 June 2027, in order to enable the company to fulfil its financial commitments as and when liabilities fall due.”
Significant events
- “Following the reporting period, the company completed the sale of its business and related assets to Quvara Medical Limited and the sale of the Swindon property to Quvara Medical Holdings Limited on 1 December 2025. Post disposal of the manufacturing business, the company transitioned from a group manufacturing entity to a warehousing and logistics hub supporting the group's operations.”
- “In March 2026, following the 30 September 2025 reporting date and before the financial statements were authorised for issue, management completed a further review of the Preventis assets within the BioPharma segment at the Swindon site. Following this review, management approved actions to realign the cost base and rationalise Preventis manufacturing capacity, including the decommissioning and scrapping of one of the two Preventis production lines and the abandonment of certain assets not yet in service due to significant excess capacity and changes in the expected future use of those assets. As part of this conclusion, management also approved the related impairment.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 25 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| GREEN, Robert John, Mr. | Director | 2022-12-21 | Jun 1973 | British |
| THOMAS, Glenn Michael, Mr. | Director | 2023-07-14 | May 1987 | British |
| WAKEFIELD, Ian Kurt | Director | 2026-05-01 | Jul 1965 | South African |
Show 25 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ARNOLD, Julie Christine | Secretary | 1998-04-01 | 2008-01-08 |
| NEYLON, Anthony | Secretary | 2008-01-08 | 2015-07-09 |
| REED, Bryan James | Secretary | — | 1998-04-04 |
| ADAMS, Alex, Country General Manager | Director | 2008-10-01 | 2015-07-09 |
| ARNOLD, Julie Christine | Director | 1998-04-01 | 2017-02-16 |
| CLOUGH, Christopher John, Dr | Director | 1997-09-15 | 1998-04-04 |
| CLUBB, Ian Mcmaster | Director | — | 1994-09-30 |
| CONNELL, William Edward | Director | — | 1998-04-04 |
| ELSEY, Keith Anthony Lambert | Director | 1998-04-01 | 2000-05-17 |
| FAIRBOURN, Michael John | Director | 2015-07-09 | 2025-12-05 |
| GIBSON, Kathleen | Director | 2001-12-11 | 2002-09-16 |
| GRANT, Richard Stanley | Director | — | 1995-04-11 |
| HANSON, Alfred John | Director | 1998-04-01 | 2007-09-30 |
| HEALY, Bridget | Director | 1999-10-01 | 2003-11-19 |
| HOPKIN, Edward Daniel | Director | 2015-02-02 | 2022-12-21 |
| ISAAC, Anthony Eric | Director | 1994-10-17 | 1998-04-04 |
| LUNDGREN, Johnny | Director | 2011-06-28 | 2015-02-02 |
| LUNDGREN, Johnny, Country General Manager | Director | 2007-03-01 | 2008-10-01 |
| NEAT, John Konrad | Director | 2015-07-09 | 2019-11-05 |
| NEYLON, Anthony | Director | 2007-03-01 | 2015-07-09 |
| PEPPER, Joseph Wheeler | Director | 1995-04-11 | 1997-05-09 |
| SAITH, Vijay Kumar | Director | — | 1998-04-04 |
| STOLL, Roger Gerhard, Dr | Director | — | 1998-04-04 |
| TARALLO, Angelo Nicholas | Director | — | 1994-06-01 |
| VENKATARAMAN, Srividhya | Director | 2019-11-05 | 2023-02-02 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Bd Uk Ltd | Corporate entity | Significant influence | 2016-09-01 | Ceased 2016-09-01 |
| Becton Dickinson Infusion Therapy Holdings Uk Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 201 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-07-10 | AA | accounts | Accounts with accounts type full | |
| 2026-05-06 | AP01 | officers | Appoint person director company with name date | |
| 2025-12-11 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-17 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-04-22 | AD02 | address | Change sail address company with old address new address | |
| 2025-04-22 | AA | accounts | Accounts with accounts type full | |
| 2025-04-17 | AD03 | address | Move registers to sail company with new address | |
| 2024-11-15 | AD02 | address | Change sail address company with new address | |
| 2024-11-15 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-04-16 | AA | accounts | Accounts with accounts type full | |
| 2023-11-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-09-16 | MR05 | mortgage | Mortgage charge whole release with charge number | |
| 2023-07-24 | AP01 | officers | Appoint person director company with name date | |
| 2023-06-26 | AA | accounts | Accounts with accounts type full | |
| 2023-02-03 | TM01 | officers | Termination director company with name termination date | |
| 2023-01-19 | TM01 | officers | Termination director company with name termination date | |
| 2023-01-19 | AP01 | officers | Appoint person director company with name date | |
| 2022-11-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-06-15 | AA | accounts | Accounts with accounts type full | |
| 2021-11-15 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.